225 related articles for article (PubMed ID: 32462022)
1. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
3. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.
Hwang HW; Ha SY; Bang H; Park CK
Cancer Res Treat; 2015 Oct; 47(4):853-61. PubMed ID: 25687855
[TBL] [Abstract][Full Text] [Related]
4. [Expression of ATAD2 in different liver lesions and its clinical significance].
Liu F; Zhou X; Ji HH; Li H; Xiang FG
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):339-343. PubMed ID: 28763839
[No Abstract] [Full Text] [Related]
5. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis.
Wu G; Liu H; He H; Wang Y; Lu X; Yu Y; Xia S; Meng X; Liu Y
BMC Cancer; 2014 Feb; 14():107. PubMed ID: 24552534
[TBL] [Abstract][Full Text] [Related]
6. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report.
Lü Y; Zhang J; Li L; Li S; Yang Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31990034
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
[TBL] [Abstract][Full Text] [Related]
8. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.
Lu WJ; Chua MS; So SK
Oncotarget; 2015 Dec; 6(39):41722-35. PubMed ID: 26497681
[TBL] [Abstract][Full Text] [Related]
10. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
11. Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling.
Wang JH; Yu TT; Li Y; Hao YP; Han L; Xu KY; Xu P
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6055-6063. PubMed ID: 32572920
[TBL] [Abstract][Full Text] [Related]
12. Up-regulated and interrelated expressions of GINS subunits predict poor prognosis in hepatocellular carcinoma.
Lian YF; Li SS; Huang YL; Wei H; Chen DM; Wang JL; Huang YH
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413605
[TBL] [Abstract][Full Text] [Related]
13. A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.
Zhao K; Zhao Y; Zhu JY; Dong H; Cong WM; Yu Y; Wang H; Zhu ZZ; Xu Q
Curr Med Sci; 2018 Aug; 38(4):590-596. PubMed ID: 30128866
[TBL] [Abstract][Full Text] [Related]
14. Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.
Liang HW; Yang X; Wen DY; Gao L; Zhang XY; Ye ZH; Luo J; Li ZY; He Y; Pang YY; Chen G
Mol Med Rep; 2018 Jan; 17(1):1469-1484. PubMed ID: 29138825
[TBL] [Abstract][Full Text] [Related]
15. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
16. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.
Zhang R; Zhang LJ; Yang ML; Huang LS; Chen G; Feng ZB
Mol Med Rep; 2018 Feb; 17(2):2211-2228. PubMed ID: 29207133
[TBL] [Abstract][Full Text] [Related]
17. Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing.
Yu Z; Wang R; Chen F; Wang J; Huang X
Dig Dis Sci; 2018 Apr; 63(4):945-957. PubMed ID: 29442275
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Tang H; You T; Sun Z; Bai C
BMC Cancer; 2022 Feb; 22(1):197. PubMed ID: 35189839
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ATAD2 indicates Poor Prognosis in Oral Squamous Cell Carcinoma.
Wang XL; Wang S; Wu ZZ; Yang QC; Li H; Xiong HG; Wan SC; Sun ZJ
Int J Med Sci; 2020; 17(11):1598-1609. PubMed ID: 32669963
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
